Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: Long-term follow up and influence of therapy

Clinical Immunology

Volumn 112, Issue 3, 2004, Pages 268-272

  Yeh, Shih Wei ^a   Usman, Adnan Q ^a   Ahmed, A Razzaque ^a,b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

Autoimmune; Basement membrane; Blistering disease; Intravenous immunoglobulin; Mucous membrane pemphigoid; Therapy

Indexed keywords

ANTIGEN; AUTOANTIBODY; BETA4 INTEGRIN; BULLOUS PEMPHIGOID ANTIGEN; IMMUNOGLOBULIN; KALININ; MEMBRANE PROTEIN; MEMBRANE ZONE PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BULLOUS SKIN DISEASE; CATTLE; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GINGIVA; HUMAN; IMMUNOBLOTTING; LONG TERM CARE; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOANTIGENS; BASEMENT MEMBRANE; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTEGRIN BETA4; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; TIME FACTORS;

EID: 4043126162     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.04.010     Document Type: Article

References (29)

1. Scully C., Carrozzo M., Gandolfo S., Puiatti P., Monteil R. Update on mucous membrane pemphigoid: a heterogeneous immune-mediated subepithelial blistering entity. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endo. 88:1999;56-68
2. Fleming T.E., Korman N.J. Cicatricial pemphigoid. J. Am. Acad. Dermatol. 43:2000;571-591. (quiz 591-594)
3. Meyer J.R., Migliorati C.A., Daniels T.E., Greenspan J.S. Localization of basement membrane components in mucous membrane pemphigoid. J. Invest. Dermatol. 84:1985;105-107
4. Dayan S., Simmons R.K., Ahmed A.R. Contemporary issues in the diagnosis of oral pemphigoid: a selective review of the literature. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endo. 88:1999;424-430
5. Scott J.E., Ahmed A.R. The blistering diseases. Med. Clin. North Am. 82:1998;1239-1283
6. Kirtschig G., Murrell D., Wojnarowska F., Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch. Dermatol. 138:2002;380-384
7. Gandhi K., Chen M., Aasi S., Lapiere J.C., Woodley D.T., Chan L.S. Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype. J. Clin. Immunol. 20:2000;416-423
8. Engineer L., Johnson R.E., Bhol K.C., Ahmed A.R. Bovine gingival lysate: a novel substrate for rapid diagnosis of autoimmune vesiculo-bullous diseases. A preliminary observation. Exp. Dermatol. 9:2000;271-274
9. Leverkus M., Bhol K., Hirako Y., Pas H., Sitaru C., Baier G., et al. Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230. Br. J. Dermatol. 145:2001;998-1004
10. Lazarova Z., Yee C., Lazar J., Yancey K.B. IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin. Immunol. 101:2001;100-105
11. Ghohestani R.F., Nicolas J.F., Rousselle P., Claudy A.L. Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid. J. Invest. Dermatol. 107:1996;136-139
12. Tyagi S., Bhol K., Natarajan K., Livir-Rallatos C., Foster C.S., Ahmed A.R. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc. Natl. Acad. Sci. U. S. A. 93:1996;14714-14719
13. Kumari S., Bhol K.C., Simmons R.K., Razzaque M.S., Letko E., Foster C.S., et al. Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin. Invest. Ophthalmol. Visual Sci. 42:2001;379-385
14. Chan R.Y., Bhol K., Tesavibul N., Letko E., Simmons R.K., Foster C.S., et al. The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest. Ophthalmol. Visual Sci. 40:1999;2283-2290
15. Bhol K.C., Colon J.E., Ahmed A.R. Autoantibody in mucous membrane pemphigoid binds to an intracellular epitope on human beta4 integrin and causes basement membrane zone separation in oral mucosa in an organ culture model. J. Invest. Dermatol. 120:2003;701-702
16. Miserocchi E., Baltatzis S., Roque M.R., Ahmed A.R., Foster C.S. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology. 109:2002;111-118
17. Foster C.S., Ahmed A.R. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology. 106:1999;2136-2143
18. Sami N., Bhol K.C., Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin. Immunol. 102:2002;59-67
19. Letko E., Bhol K., Foster S.C., Ahmed R.A. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study. Curr. Eye Res. 21:2000;646-654
20. Bhol K.C., Dans M.J., Simmons R.K., Foster C.S., Giancotti F.G., Ahmed A.R. The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4. J. Immunol. 165:2000;2824-2829
21. Bhol K.C., Goss L., Kumari S., Colon J.E., Ahmed A.R. Autoantibodies to human alpha6 integrin in patients with oral pemphigoid. J. Dent. Res. 80:2001;1711-1715
22. Balding S.D., Prost C., Diaz L.A., Bernard P., Bedane C., Aberdam D., et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J. Invest. Dermatol. 106:1996;141-146
23. Colon J.E., Bhol K.C., Razzaque M.S., Ahmed A.R. In vitro organ culture model for mucous membrane pemphigoid. Clin. Immunol. 98:2001;229-234
24. Domloge-Hultsch N., Anhalt G.J., Gammon W.R., Lazarova Z., Briggaman R., Welch M., et al. Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch. Dermatol. 130:1994;1521-1529
25. Sami N., Ali S., Bhol K.C., Ahmed A.R. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J. Eur. Acad. Dermatol. Venereol. 17:2003;641-645
26. Sami N., Bhol K.C., Ahmed A.R. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin. Immunol. 105:2002;192-198
27. Jolles S. High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin. Exp. Immunol. 129:2002;385-389
28. Rutter A., Luger T.A. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Curr. Opin. Invest. Drugs. 3:2002;713-719
29. Kobayashi M., Amagai M., Kuroda-Kinoshita K., Hashimoto T., Shirakata Y., Hashimoto K., et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J. Dermatol. Sci. 30:2002;224-232